Lithuania vs Sur: The number of people with susceptibility test result for rifampicin
Lithuania
100
in 2021
Sur
97.1
in 2021
Lithuania rank
2nd
Sur rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Lithuania
- Sur
How they compare
Lithuania currently reports 100 against 97.1 in Sur, a difference of 2.9.
Across all 5 years both countries report, Lithuania has been ahead every year.
Lithuania ranks 2nd and Sur ranks 2nd of 146 countries.
Lithuania has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Lithuania | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 100 | 86.78 | 13.22 | Lithuania |
| 2020s | 100 | 97.8 | 2.2 | Lithuania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Lithuania or Sur?
- Lithuania, at 100 against 97.1 in Sur as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Lithuania and Sur?
- 2.9, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Sur?
- 5 years are reported by both, from 2017 to 2021.
- How do Lithuania and Sur rank globally for the number of people with susceptibility test result for rifampicin?
- Lithuania ranks 2nd and Sur ranks 2nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.